Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoCath CE-marks second cardiac ablation catheter:

This article was originally published in Clinica

Executive Summary

CryoCath Technologies has gained the go-ahead to sell its second cardiac ablation catheter in Europe. The Freezor Xtra device can create lesions that are significantly larger than those of the firm's original Freezor catheter, allowing surgeons to treat arrhythmias further from the AV node that require more robust lesions - such as atrial fibrillation, and ventricular tacchycardia. The Kirkland, Quebec firm plans to file for US approval for the original Freezor device in the autumn of next year. It forecasts that US approval for the Xtra catheter could come in 2004.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel